These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10541358)

  • 1. Radioimmunotherapy using vascular targeted 213Bi: the role of tumor necrosis factor alpha in the development of pulmonary fibrosis.
    Davis IA; Kennel SJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3160s-3164s. PubMed ID: 10541358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi.
    Kennel SJ; Boll R; Stabin M; Schuller HM; Mirzadeh S
    Br J Cancer; 1999 Apr; 80(1-2):175-84. PubMed ID: 10389994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination vascular targeted and tumor targeted radioimmunotherapy.
    Kennel SJ; Lankford TK; Foote LJ; Davis IA; Boll RA; Mirzadeh S
    Cancer Biother Radiopharm; 1999 Oct; 14(5):371-9. PubMed ID: 10850322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular targeted radioimmunotherapy with 213Bi--an alpha-particle emitter.
    Kennel SJ; Mirzadeh S
    Nucl Med Biol; 1998 Apr; 25(3):241-6. PubMed ID: 9620629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of lung tumor colonies with 90Y targeted to blood vessels: comparison with the alpha-particle emitter 213Bi.
    Kennel SJ; Stabin M; Yoriyaz H; Brechbiel M; Mirzadeh S
    Nucl Med Biol; 1999 Jan; 26(1):149-57. PubMed ID: 10096515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
    Kennel SJ; Mirzadeh S; Eckelman WC; Waldmann TA; Garmestani K; Yordanov AT; Stabin MG; Brechbiel MW
    Radiat Res; 2002 Jun; 157(6):633-41. PubMed ID: 12005541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.
    Bloechl S; Beck R; Seidl C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7070s-7074s. PubMed ID: 16203804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis.
    Miyazaki Y; Araki K; Vesin C; Garcia I; Kapanci Y; Whitsett JA; Piguet PF; Vassalli P
    J Clin Invest; 1995 Jul; 96(1):250-9. PubMed ID: 7542280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
    Akabani G; Kennel SJ; Zalutsky MR
    J Nucl Med; 2003 May; 44(5):792-805. PubMed ID: 12732682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors.
    Kennel SJ; Chappell LL; Dadachova K; Brechbiel MW; Lankford TK; Davis IA; Stabin M; Mirzadeh S
    Cancer Biother Radiopharm; 2000 Jun; 15(3):235-44. PubMed ID: 10941530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.
    Senekowitsch-Schmidtke R; Schuhmacher C; Becker KF; Nikula TK; Seidl C; Becker I; Miederer M; Apostolidis C; Adam C; Huber R; Kremmer E; Fischer K; Schwaiger M
    Cancer Res; 2001 Apr; 61(7):2804-8. PubMed ID: 11306447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung.
    Zhang M; Qian J; Xing X; Kong FM; Zhao L; Chen M; Lawrence TS
    Clin Cancer Res; 2008 Mar; 14(6):1868-76. PubMed ID: 18347190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
    Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
    J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is "tumor necrosis factor" the major effector of pulmonary fibrosis?
    Piguet PF
    Eur Cytokine Netw; 1990; 1(4):257-8. PubMed ID: 1716490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
    Kelly MP; Lee FT; Tahtis K; Smyth FE; Brechbiel MW; Scott AM
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5604s-5612s. PubMed ID: 17875796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The pivotal role of CXCR3 in the pathogenesis of bleomycin-induced pulmonary fibrosis].
    Gao JM; Lu B
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Jan; 28(1):28-32. PubMed ID: 15774188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
    Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
    J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary tuberculosis in BALB/c mice with non-functional IL-4 genes: changes in the inflammatory effects of TNF-alpha and in the regulation of fibrosis.
    Hernandez-Pando R; Aguilar D; Hernandez ML; Orozco H; Rook G
    Eur J Immunol; 2004 Jan; 34(1):174-83. PubMed ID: 14971043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
    Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efforts to control the errant products of a targeted in vivo generator.
    Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
    Cancer Res; 2005 Jun; 65(11):4888-95. PubMed ID: 15930310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.